IMNNHealthcare · BiotechnologyThe 4 Wall Street analysts covering Imunon, Inc. hold a median 12-month price target of $13 — +692.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Imunon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IMNN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +692.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Apr 2026 | Maxim Group | Initiates | Buy | $10 |
| 19 May 2025 | D. Boral Capital | Downgrade | Hold | — |
| 13 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 25 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2024 | EF Hutton | Maintains | Buy | — |
| 31 Oct 2024 | EF Hutton | Maintains | Buy | — |
| 23 Sept 2024 | EF Hutton | Initiates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMNN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 27% of US stocks
Cheaper than 66% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Imunon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Imunon, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management discussion.
Why it matters — A transcript of the Q2 2026 earnings call provides IMNN watchers with direct access to management's commentary on the company's financial performance.
IMUNON reported stronger-than-expected enrollment in its Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer, citing promising survival data and a well-tolerated safety profile from its earlier Phase 2 study. Enrollment is ahead of plan across all study sites, with additional sites opening on schedule.
Why it matters — Ahead-of-plan enrollment and principal investigator confidence in the trial design signal positive momentum for IMNN-001, a key pipeline asset for the company.
The 4 Wall Street analysts covering Imunon, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Imunon, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Imunon, Inc. 22 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Imunon, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +692.7% from the last close, and Ticker Nerd's factor model ranks Imunon, Inc. 22 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Imunon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.
Imunon, Inc. returned -75.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies and DNA-based vaccines aimed at treating challenging diseases.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript". Imunon, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management discussion.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies and DNA-based vaccines aimed at treating challenging diseases. The company's leading program, IMNN-001, is a DNA-based immunotherapy in Phase II clinical trials targeting localized ovarian cancer. Beyond this, Imunon advances several preclinical candidates, including a COVID-19 booster vaccine and therapies for viral infections like Lassa fever and cancers such as melanoma. Utilizing proprietary non-viral DNA technology platforms—TheraPlas and PlaCCine—Imunon harnesses genetic coding to stimulate targeted immune responses, addressing solid tumors and infectious agents effectively. Founded in 1982 and headquartered in Lawrenceville, New Jersey, Imunon operates at the intersection of immunology and genetic therapy, striving to bring new therapeutic options to patients facing difficult-to-treat conditions. The company's focused pipeline and technological platforms position it as a notable player in the biotechnology and healthcare sectors.
CEO Dr. Stacy R. Lindborg Ph.D. · 25 employees · United States · https://imunon.com